Kanamycin monosulfate is a fermentation-derived aminoglycoside antibiotic active pharmaceutical ingredient recovered from selected strains of Streptomyces kanamyceticus. The monosulfate designation identifies the 1:1 stoichiometric sulfate salt of kanamycin A, with nominal formula C₁₈H₃₆N₄O₁₁·H₂SO₄, molecular weight 582.58 g/mol on the anhydrous basis, and CAS registry 25389-94-0. Pharmaceutical-grade lots are supplied as white to off-white crystalline powder, freely soluble in water and practically insoluble in ethanol, acetone, and chloroform. The API is intended for formulation into tablets, capsules, granules, and injectable solutions for oral and parenteral administration. Compendial alignment is normally established against the USP Kanamycin Sulfate monograph and the corresponding Ph.Eur. monograph; potency is expressed as kanamycin A activity and is not less than 750 µg/mg on the dried basis. Commercial packaging typically comprises double low-density polyethylene liners inside aluminum-foil laminate bags, with fiber drums of 10–25 kg net fill.

What Limits Oral Kanamycin Monosulfate Systemic Use in Tablet and Capsule Therapy?

Oral kanamycin monosulfate is not a systemic dosage strategy. The molecule is a highly polar polycation at intestinal pH, and transepithelial absorption across intact small-intestinal mucosa is minimal; therefore oral tablets, capsules, and granules act locally within the gastrointestinal lumen. This route is used for preoperative bowel preparation and for reduction of ammonia-producing or urease-producing flora in selected hepatic encephalopathy regimens, but published data for this specific configuration are limited and neomycin or rifaximin are more commonly referenced in current guidelines. Formulation design for oral products must control disintegration rather than release rate, because the API is soluble in mucosal fluid and systemic absorption is not the release-limiting step. Disintegration testing follows USP 701; for immediate-release tablets and capsules, a 30 minute disintegration acceptance criterion is common in the absence of a product-specific override. Enteric coating is generally unnecessary for local action. Granule dosage forms should be protected from moisture because caking of the water-soluble API can alter content uniformity and dosing accuracy.

In high-shear tablet and capsule manufacture, kanamycin monosulfate is commonly incorporated by aqueous wet granulation. A 300 L vertical high-shear granulator with impeller tip speed 5–12 m/s and a fluid-bed drier with inlet air at 45–55 °C represent typical processing ranges; endpoint is determined by loss-on-drying of 1.0–2.5% and granule particle-size distribution, not by fixed granulation time. Because the API is water-soluble, binder addition can rapidly produce overwet masses; torque monitoring and in-process particle-size analysis are required. Roller compaction may be evaluated for direct-compression blends to avoid excessive fines segregation. Published shear-cell flow function data for kanamycin sulfate are limited; a Schulze ring shear tester operated per ASTM D6773 should be employed to establish flow function coefficient before commissioning a high-speed tablet press. Tablet breaking force and friability are tested per USP 1217 and USP 1216, respectively. Magnesium stearate is maintained below 1.0% w/w in the final blend to avoid dissolution and disintegration retardation. For capsule filling, the dried granulation is sized through an oscillating mill with 0.8–1.25 mm screen and filled into hard gelatin or HPMC capsules to a target fill weight determined by potency assay. Content uniformity is assessed per USP 905. Because fermentation-derived titer and downstream crystallization can introduce batch-to-batch particle-size and residual solvent variation, blend uniformity and potency adjustment are performed per lot using assay results.

Injectable Processing, Endotoxin Control, and Particulate Standards

For parenteral use, kanamycin monosulfate is dissolved in Water for Injection and filled as a solution. Injectable-grade API must meet low bioburden, bacterial endotoxin, and particulate controls appropriate for the final product. Endotoxin is controlled at not more than 0.67 EU/mg for materials intended for injection, tested by Limulus amebocyte lysate per USP 85 or Ph.Eur. 2.6.14. Sterile filtration through 0.2 µm polyethersulfone or polyvinylidene fluoride membranes is used before aseptic filling when terminal sterilization is not selected. If terminal moist-heat sterilization is used, the cycle is validated with container-mapping and biological indicators per ISO 17665-1; the API solution should be protected from prolonged alkaline conditions and from headspace oxygen during heating. Subvisible particulate matter in the finished injection must comply with USP 788 limits, typically not more than 6000 particles per container at ≥10 µm and 600 per container at ≥25 µm for small-volume parenterals. Visual inspection follows USP 790, and container-closure integrity testing is required for the selected closure system. Kanamycin injection is incompatible in the same intravenous admixture with beta-lactam antibiotics because aminoglycosides can be chemically inactivated by covalent penicillin or cephalosporin adducts; separate infusion lines or sequential flushing is required. Finished injectable solution pH is adjusted to the compendial target, and osmolality is controlled to avoid pain on intramuscular injection. Intravenous infusion is diluted in 0.9% w/v sodium chloride or 5% dextrose injection. Phosphate-buffered diluents should be avoided when calcium or magnesium is present because precipitation may occur, and aminoglycosides can potentiate neuromuscular blockade with magnesium sulfate.

When Kanamycin Monosulfate Replaces Amikacin or Gentamicin in a Formulation

Kanamycin monosulfate is not interchangeable with amikacin sulfate or gentamicin sulfate on a milligram-per-milligram basis. Amikacin is a semisynthetic derivative of kanamycin A bearing a L-(-)-4-amino-2-hydroxybutyryl substituent at the N1 amino group; this modification reduces affinity for many aminoglycoside-modifying enzymes and extends activity against some gentamicin-resistant and kanamycin-resistant Enterobacterales. Kanamycin remains useful in second-line parenteral treatment of susceptible Mycobacterium tuberculosis, but its place in hospital-acquired Gram-negative sepsis has narrowed where amikacin, gentamicin, or tobramycin are active. Gentamicin sulfate is a fermentation complex of C1, C1a, and C2 components and generally demonstrates greater antipseudomonal activity than kanamycin. Neomycin sulfate, another oral aminoglycoside, has more pronounced mucosal and renal toxicity potential and is used mainly for bowel preparation or topical therapy. Differences in potency, dosing units, and impurity profiles require that each formulation be developed independently rather than by direct molar substitution. Kanamycin monosulfate has no ultraviolet chromophore; assay and related-substance methods therefore rely on derivatization, ion-pair chromatography with pulsed amperometric detection, or aerosol-based detection, whereas other APIs may be monitored by direct UV absorbance.

Thermal and humidity stress studies for kanamycin sulfate solid oral products are conducted according to ICH Q1A(R2) at 25°C/60% RH, 30°C/65% RH, and 40°C/75% RH. The API can absorb moisture under elevated relative humidity; bulk containers should be reclosed under nitrogen and stored below 25°C in a dry area. In uncoated tablets and granules, moisture uptake above 60% RH can produce surface dulling and caking. Stability-indicating methods typically use ion-pair reversed-phase HPLC with pulsed amperometric detection or ELSD because kanamycin lacks a strong chromophore. Degradation is accelerated by strongly acidic or strongly alkaline conditions and by prolonged exposure to oxidizing agents; kanamycin sulfate aqueous solutions should be protected from light and stored in inert containers. Published kinetic data for kanamycin monosulfate in specific tablet matrices are limited; each formulation should be validated by forced-degradation studies per ICH Q1B. Granule dosage forms for oral use are often blended with hydrophobic glidants to limit moisture sorption during storage in HDPE bottles. If moisture protection is required, desiccant canisters containing silica gel or molecular sieve are inserted; desiccant mass is calculated from the container water-vapor transmission rate and the product sorption isotherm. Published sorption isotherm data for kanamycin sulfate are limited; therefore, equilibrium moisture content should be measured by dynamic vapor sorption before packaging specifications are fixed.

Residual Solvent and Elemental Impurity Control Follows ICH Q3C and Q3D

Residual solvent testing is performed by headspace gas chromatography per USP 467 and ICH Q3C. Ethanol, methanol, acetone, and isopropanol are controlled to Class 3 limits; if any Class 2 solvent is used in crystallization, its limit is applied to the parenteral and oral permitted daily exposures. Elemental impurities are controlled per ICH Q3D and USP 232/233; samples are digested and analyzed by inductively coupled plasma mass spectrometry or optical emission spectroscopy. Because fermentation and downstream processing may involve stainless steel equipment, nickel and chromium recovery should be monitored. The sulfate counterion can influence the choice of elemental impurity analytical method; sulfate matrices should be evaluated for interferences in ICP-MS. Suppliers of pharmaceutical-grade kanamycin monosulfate provide a certificate of analysis with each lot, and the drug product manufacturer is responsible for verifying compendial compliance and evaluating supplier change notifications under ICH Q7. The API should not be blended with strong oxidizing agents, strong acids, or materials that generate reactive carbonyl species, because these can degrade the aminoglycoside nucleus and increase impurity levels.

Commercially, pharma-grade kanamycin monosulfate differs from non-pharma grades in sterile-filterable bioburden, endotoxin control, residual solvent documentation, and compendial analytical traceability. For tablet and capsule applications, the low bioburden specification is less critical than for injection, but endotoxin and impurity profiles remain important because oral products for bowel preparation may be used at high total daily doses. For injectable products, the API must be processed in classified environments and released only after sterility, endotoxin, and particulate testing of the finished product. The monosulfate salt should be specified as kanamycin sulfate in regulatory dossiers; the term monosulfate is used to distinguish the 1:1 sulfate salt from kanamycin acid sulfate or other salt forms. Repackaging into polyethylene-lined fiber drums under nitrogen and storage at not more than 25°C with desiccated closures is recommended for tropical climates.